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Abstract
Background: A standard task in pharmacogenomics research is identifying genes that may be involved in drug
response variability, i.e., pharmacogenes. Because genomic experiments tended to generate many false positives,
computational approaches based on the use of background knowledge have been proposed. Until now, only
molecular networks or the biomedical literature were used, whereas many other resources are available.
Method: We propose here to consume a diverse and larger set of resources using linked data related either to genes,
drugs or diseases. One of the advantages of linked data is that they are built on a standard framework that facilitates
the joint use of various sources, and thus facilitates considering features of various origins. We propose a selection and
linkage of data sources relevant to pharmacogenomics, including for example DisGeNET and Clinvar. We use machine
learning to identify and prioritize pharmacogenes that are the most probably valid, considering the selected linked
data. This identification relies on the classification of gene–drug pairs as either pharmacogenomically associated or
not and was experimented with two machine learning methods –random forest and graph kernel–, which results are
compared in this article.
Results: We assembled a set of linked data relative to pharmacogenomics, of 2,610,793 triples, coming from six
distinct resources. Learning from these data, random forest enables identifying valid pharmacogenes with a
F-measure of 0.73, on a 10 folds cross-validation, whereas graph kernel achieves a F-measure of 0.81. A list of top
candidates proposed by both approaches is provided and their obtention is discussed.
Keywords: Linked data, Pharmacogenomics, Data mining, Knowledge discovery from databases, Machine learning,
Valid pharmacogenes
Background
Pharmacogenomics (PGx) studies how individual gene
variations cause variability in drug responses [1]. Well
established knowledge in PGx constitutes a basis for
implementing personalized medicine, i.e., a medicine tai-
lored to each patient by considering in particular her/his
genomic context. The state of the art of this domain
lies both in the biomedical literature and in specialized
databases [2, 3], but a large part of it is controversial,
and not yet applicable to medicine. Indeed, this results
from studies difficult to reproduce and that do not fulfill
statistical validation standards for two main reasons: the
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small size of populations involved in studies because of
the rarity of gene variants studied and the potential coac-
tion of several variants [4, 5]. It is consequently of interest
to the PGx community to explore any source of evidence
that may contribute to confirming or moderating PGx
state of the art. So far, existing works used either molec-
ular network databases or the biomedical literature (see
“Discovery of pharmacogenes” subsection). We propose
in this work to explore how other resources, and partic-
ularly Linked Open Data (LOD) may be useful in this
domain.
Linked open data
LOD are constituting a large and growing collection of
datasets that present the main advantages of being rep-
resented in a standard format (based on both RDF and
URIs) and partially connected to each other and to domain
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knowledge represented within semantic web ontologies
[6]. For these reasons, LOD offer novel opportunities
for the development of successful data integration and
knowledge discovery campaign, as required for the dis-
covery of novel pharmacogenes. LOD are part of a com-
munity effort to build a semantic web, where web and
data resources can be interpreted both by humans and
machines. The recent availability of LOD is particularly
beneficial to the life sciences, where relevant data are
spread over various data sources with no agreement on
a unique representation of biological entities [7]. Conse-
quently, data integration is an initial challenge one faces
if one wants to mine life science data considering sev-
eral data sources. Various initiatives such as Bio2RDF, the
EBI platform, PDBj and Linked Open Drug Data (LODD)
aim at pushing life sciences data into the LOD cloud with
the idea of facilitating their integration [8–11]. It results
from these initiatives a large collection of life-science data,
unequally connected but in a standard format and avail-
able for mining. Despite good will and emerging standard
practices for publishing data as LOD, several drawbacks
make their use still challenging [12, 13]. Among exist-
ing difficulties we can cite the limited amount of links
between datasets and the limits of implementations of
federated queries.
Pharmacogenomics data and linked data
PharmGKB is a comprehensive database about PGx that
includes manually annotated gene–drug relationships [3].
Recently, annotations of PharmGKB have been completed
with a level of evidence going from 1 to 4, distinguish-
ing well validated gene–drug relationships (level= 1 − 2)
from insufficiently validated ones (3–4), thus point-
ing at knowledge in need for additional investigations
[14]. PharmGKB does not provide its data in RDF, but
parts of PharmGKB have been transformed and pub-
lished in RDF by contributors of the Bio2RDF project,
thus enabling SPARQL queries [15]. Clinical annotations
of PharmGKB are however not freely available. Their
usage is granted through a license agreement, prevent-
ing the data from being redistributed, thus published
as Linked Open Data. Many other databases provides
data that are indirectly relevant to PGx. For instances,
DrugBank [16] provides drug–target relationships; Clin-
Var [17] provides gene variant–phenotype relationships;
SIDER [18, 19] and Medi-Span provides drug–phenotype
relationships such as drug adverse events or indications
[20]. Medi-Span is a proprietary database of Wolters
Kluwer Health (Indianapolis, IN) aiming at providing
drug clinical data to clinicians. DGIdb (The Drug Gene
Interaction database) is another interesting initiative that
integrates quasi-exhaustively data about gene–drug rela-
tionships, considering 15 distinct sources [21]. DisGenet
is a data integration initiative that focuses on gene–disease
relationships and provides data in RDF, including parts of
ClinVar and OMIM [22].
Data integration effort clearly oriented to PGx applica-
tions are less common, particularly if considering seman-
tic web approaches [23]. Hoehndorf et al. integrated and
made available a set of PGx related data that includes
PharmGKB, DrugBank and CTD (the Comparative Tox-
icogenomics Database), using semantic web technologies
[24]. They used the integrated dataset to identify pathways
that may be perturbed in PGx. In this effort of publish-
ing PGx data, Coulet et al. extracted about 40,000 PGx
relationships from the biomedical literature and published
them in the form of RDF statements [25].
Mining linked data
Suggesting valid pharmacogenes in this work is seen as
proposing novel gene–drug relationships from an RDF
graph, which in turn can be described as a link prediction
problem. Many works have focused on the link prediction
problem, studying various approaches such as machine
learning [26, 27], graph mining [28–30], identity resolu-
tion [31, 32] and data visualisation [33]. Some of these
methods obtain good results, but all are dependent from
the input graphs (its quality, topology, etc.) and are hard
to reuse for new applications. Recently, de Vries and de
Rooij proposed a complete framework for applying Graph
Kernel (GK) in an adaptive manner to RDF graphs [34].
GK are machine learning methods that have the ability to
deal directly with graph data, particularly by computing
kernel functions that evaluate similarity between graphs
or pieces of graphs [35]. The framework of de Vries and
de Rooij is implemented in an open source library named
Mustard [36]. It enables classifying RDF instances consid-
ering their neighborhood in the graph. This neighborhood
is encoded within features such as labels of edges or graph
substructures such as walks (i.e., linear paths) or sub-
graphs. In the work we present here, we reused Mustard
and fitted its capability of instance classification to the
case of link prediction.
In relation with PGx research, Percha et al. mined the
set of RDF statements extracted from text by Coulet et al.
with a Random Forest (RF) algorithm and successfully
predicted drug–drug interactions [37]. With the aim of
predicting pharmacogenes, we experimented as Percha
et al. with the RF algorithm in the preliminary stage of
this work [38]. First results we obtained with RF are here
updated and compared with GK approaches.
Discovery of pharmacogenes
Hansen et al. proposed a method based on a logistic clas-
sifier to generate candidate pharmacogenes, using data
from PharmGKB, DrugBank, and protein–protein inter-
actions from InWeb [39]. An issue with this approach
is that PharmGKB and DrugBank are manually curated
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from the literature and are consequently expensive to
maintain and update. Garten et al. answered this issue
by proposing an automatic method that consider directly
(and only) the literature [40]. They improved the results
obtained by Hansen et al. by considering gene–drug pairs
co-occurring in sentences of the PGx literature. Recently,
Funk et al. proposed also to use the biomedical literature,
plus GO annotations, to identify pharmacogenes [41].
They obtain a high F-measure and AUC-ROC (0.86 and
0.86), but proposed a coarse-grained classification that is
only binary (pharmacogene or not), avoiding any ranking
of the candidates.
Semantic web technologies have also been experi-
mented for PGx knowledge discovery. Dumontier and
Villanueva-Rosales proposed a knowledge representation
of the domain and benefit from reasoning mechanisms
to answer sophisticated queries related to depression
drugs [42]. Coulet et al. used patient data to instantiate a
description logics knowledge base, then extracted associ-
ation rules from it to identify gene variant–drug response
associations [43]. More generally, advantages that seman-
tic web technologies may offer to PGx and personalized
medicine are listed in [23].
We present here a method that consists in mining a set
of diverse linked data sources to help validating uncer-
tain gene–drug relationships. This method can be divided
in three steps: first, selecting and connecting relevant
PGx linked data; second, formatting linked data to train
and compare two machine learning algorithms (RF and
GK); third, classify and rank candidate pharmacogenes
with these two approaches. The paper is organized as
follow: next section presents our methods for preparing,
then learning from the linked data; next, Results Section
presents the evaluation and the use of the two machine
learning approaches we considered and brings elements
of interpretation; the two last sections discuss our results
and conclude on this work.
Methods
Data preparation
Data selection Initial step is to select a set of data that
include relevant data about PGx gene–drug relationships.
Figure 1 gives a general overview of the type of data we
consider for this study: three types of entities, gene, pheno-
type and drug; and relationships between them, i.e., gene–
phenotype, phenotype–drug and gene–drug relationships.
Fig. 1 Overview of the type of entities and relationships considered and their origin. Entities are of three distinct types: Gene, Phenotype and Drug.
Gene–Phenotype relationships are coming from ClinVar and DisGeNET, Phenotype–Drug relationships from SIDER and Medi-Span, Gene–Drug
relationships from DrugBank. In addition, we included gene and drug entities from PharmGKB to enable building the training and test sets.
Equivalence mappings are defined between entities of the same type but of different origin. In addition to entity–entity relationships, we consider
some attributes that are specific to entities, such as the ATC class of drug that is a drug attribute. Naming of different parts of the data (e.g., G–P links,
gene attributes) is used later in the step of formatting of the linked data. The detailed schema of the data is provided Fig. 2
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We selected data sources manually but oriented our selec-
tion to sources providing typed relationships and limited
ourselves to two sources per relationship. As a result,
we selected ClinVar and DisGeNET for gene–phenotype;
SIDER andMedi-Span for phenotype–drug; DrugBank for
gene–drug relationships. PharmGKB completes the set of
data sources to enable building the training and test sets
(see “Training and test sets” subsection).
Data RDFization The second step is about turning
selected data in a standardized RDF graph, available at
https://pgxlod.loria.fr. We benefit from the fact that Dis-
GeNET [44], SIDER [45] and DrugBank [46] are already
available online in the form of LOD and reused them.
DisGeNET includes data from ClinVar, but because it
includes only a part of it, we made our own RDF
version of ClinVar following guidelines and scripts of
the Bio2RDF project. We completed the Bio2RDF ver-
sion of PharmGKB locally with gene–drug relationships
manually annotated by PharmGKB but not openly dis-
tributed [15]. Similarly, we transformed drug indications
and side-effects from Medi-Span in the form of RDF
triples and loaded them into our SPARQL server. For
the management of RDF data, we rely on Blazegraph, a
graph database system that provides support for RDF and
SPARQL. Medi-Span data, as PharmGKB clinical anno-
tations are protected by a license agreement and can not
be redistributed. This explains why we are providing a
controlled access to our set of PGx linked data. We pro-
pose to open this dataset, on demand, with licensees.
Figure 2 presents the detailed schema (i.e., type of enti-
ties and relationships) of the linked data we selected and
consider for mining. Figure 3 presents an example of
data from the PGx linked data, instantiating the schema
presented Fig. 2. The SPARQL query returning data pre-
sented in Fig. 3 is provided in Additional file 1. Other
SPARQL queries, such as the one provided in Additional
file 2, may be built by considering the partial data schema
presented Fig. 2.
Mapping definition To define mappings, we first relied
on standard identifiers such as NCBI Gene ID found in
DisGeNET and ClinVar URIs and UMLS CUI found in
DisGeNET, ClinVar, SIDER and Medi-Span. We defined
regular expressions over URIs to isolate identifiers and
when twomatch, we define amapping. Figure 3 shows two
Fig. 2 Schema of the pharmacogenomic linked data selected for this study. Entities are related to either Genes, Phenotypes (or Diseases) or Drugs.
We artificially enriched the data with an additional type of entity: gene–drug pairs. These entities link exactly one gene and one drug and are the
nodes of the graph we classify either as associated or not associated from a PGx point of view, to valid candidate pharmacogenes. For mapping
purposes, we added to our dataset Gene references from UniProt and Drug references from PubChem. Because part of Medi-Span and part of
PharmGKB data are protected, we restricted the online access to the data
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Fig. 3 Sample of PGx linked data, surrounding the gene–drug pair between the EGFR gene and Carboplatin. Entities of same type but of different
provenance are mapped to each other. This graph data are used to build features describing this particular gene–drug pair. Additional file 1
provides the SPARQL query that returns this graph when applied to our selection of linked data. Prefixes used in this figure, such as dbv, are fully
expanded in the Additional file 1
entities, clinvar:1956 and disgenet:1956 that
share a unique identifier within different namespaces.
Second, when no standard identifier exists, we relied on
services provided by biodb.jp to obtain cross-references
between identifiers and, accordingly, define mappings
[47]. We implemented a tool named biojp2rdf that trans-
forms the cross-references provided by biodb.jp in RDF
[48]. For drugs, we also relied on the API provided by
RxNav to obtain mappings betweenMedi-Span identifiers
and UMLS CUIs [49]. We loaded all mapping data into
our SPARQL server to enable the resolution of identity
between entities of the same type.
Learning task, training and test sets
Learning task Our learning task is a supervised clas-
sification of specific nodes from the data graph. Nodes
considered for classification represent candidate pairs of
one gene and one drug, which are binary classified as
either pharmacogenomically associated or not. Each can-
didate pair is added to the data graph as a new node
linked to both the gene and the drug constituting the pair.
Figure 3 provides an example of such a pair and its links to
its constituents.
Training set To constitute our training set we defined
two sets of instances: positives and negatives. Our set
of positives is gene–drug pairs annotated as associated
according to PharmGKB (version of October 1st , 2015)
and that are annotated with a high level of validation in
PharmGKB, i.e., level= 1 or 2 [14]. PharmGKB clinical
annotations are relating gene variants to drugs, not gene
to drugs. We generalized these relationships to manipu-
late gene–drug relationships. When 2 variants of a same
gene are associated with two distinct levels of evidence to
the same drug, we conserve only the highest. For instance,
the VKORC1 gene has several variants associated to war-
farin with level of evidence from 1 to 4. We conserve only
that the VKORC1 gene is associated to warfarin with a
level of evidence 1. Accordingly, we generated 91 positive
instances.
To constitute our set of negatives, we randomly gener-
ated gene–drug pairs from those listed in PharmGKB, but
checked to be absent from DGIdb (the Drug Gene Inter-
action database), which collects gene–drug relationships
from various sources [21], including PharmGKB. Two dis-
tinct sets of negatives were generated, one of 91 instances
to balance exactly with the number of positives and one of
182, to experiment with this unbalance.
Test setWe considered the 1760 gene–drug pairs insuffi-
ciently validated according to PharmGKB, i.e., associated
with a level of evidence 3 or 4.
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Learning pharmacogenes with Random Forests
The Random Forest algorithm Introduced by Leo
Breiman in 2001 [50], Random Forest (RF) is an ensem-
ble method, combining decision trees in order to obtain
better results in supervised learning tasks. Let X and Y
compose a training set, where X = 〈x1, x2, ..., xn〉 is a vec-
tor of feature vectors and Y is a vector of classes Y =
〈y1, y2, ..., yn〉. A class yi is accordingly associated with each
feature vector xi. In the case of a binary classification, each
vector xi is associated with a value yi that is either 0 or 1.
The method begins by creating several new learning sets,
each one being a sample –with replacement– of elements
from X; described by their classes and a sample of their
features. A decision tree is then trained on each learn-
ing set to take part in a majority vote, which result is the
result of the RF. This approach enables a better accuracy
and generalization of the model, and counterbalances the
instability of decision trees, a forest being more stable to
slight changes in the data.
Data formatting with RF Linked data are in the form
of graphs, whereas machine learning algorithms such as
RF take a feature matrix as an input. Consequently, our
PGx linked data requires to be formatted in the form of
such a matrix. Each line of a feature matrix represents an
instance and each column represents a feature describ-
ing the instances. We propose encoding parts of the RDF
graph by observable paths that start from the gene and
the drug of a gene–drug pair. These paths start from the
gene or the drug and potentially reach each others. To
contain the size of the matrix, we simplify paths from
genes and drugs in path of length 1, hereafter named G–
D link, G–P link or D–P link, depending on the entity
that are connected. In addition to these links, we encode
few attributes that qualify drugs, genes themselves and
phenotypes that are connected to them through G–P or
D–P links. Figure 1 summarizes the elements of the graph
we consider in this formatting step. Because several paths
may leave a gene or drug, one gene–drug pair may be
described in the matrix by several instances. But each
instance describes a unique pair. A pair is thus described
by the set of instances that represent possible combina-
tions of paths and attributes associated with a pair. As
an example, Table 1 shows the matrix obtained when
formatting the sample of linked data represented in Fig. 3.
Multi-instance classification and candidate ranking
With RF classification and GK, a probability distribution
value, denoted pRF or pGK , may be used to evaluate the
confidence of the model for classifying a new instance
and then rank classified instances. However, the gene–
drug pairs that we classify are typical examples of multi-
instance objects, also named bag of instances, since they
are not represented by a single instance but by several
ones. Additional treatment is then required to classify and
rank bags of instances. One option, as seen in [51], is to
use the max operator, such that pi = max pij, where pi is
the probability estimate for the bag i, and pij the probabil-
ity estimates of all instances j of the bag i. Another option
would be to compute the arithmetic mean p̄ of proba-
bilities of instances of the bag [52]. However, one bag of
instances can contain at the same time instances classi-
fied as positive and instances classified as negative in our
case, all with a high pij. In this case, applying the max or
the arithmeticmean operator would lead to false positives.
We choose to use a weighted mean to aggregate all the pij.
Let ni be the number of instances in the bag Bi and Classij
the classification decision proposed by the model for the
instance j of the bag Bi.
pi =
∑ni
j=1 a × pij
ni
, with a =
{ −1 if Classij = 0
1 if Classij = 1
(1)
For each bag Bi, pi ∈ [−1, 1]. If every instance of a bag is
associated with a strong confidence for being classified as
positive (Classij = 1), then pi will be close to 1. In the case
of a bag of instances associated with a strong confidence
for a negative classification, pi will be close to -1. pi close
to 0means that we cannot classify, positively or negatively,
the bag with a strong confidence.
Learning pharmacogenes with graph kernels
Data formatting for graph kernel Graph Kernels (GK)
present the advantage of handling directly data in the
form of graphs. In addition, the Mustard library that we
Table 1 Example of a feature matrix generated from linked data
ID Gene attribute Phenotype Drug attribute G-D link G-P link D-P link Class
PA7360-PA131301952 Signal transduction C0007131 L01XE2 Antagonist clinvar: so_0001575 sider: indication 1
PA7360-PA131301952 Immune system C0007131 L01XE2 Antagonist clinvar: so_0001575 sider: indication 1
PA7360-PA131301952 Signal transduction C0007131 L01XE2 Antagonist clinvar: so_0001619 sider: indication 1
PA7360-PA131301952 Immune system C0007131 L01XE2 Antagonist clinvar: so_0001519 sider: indication 1
All the instances (e.g., lines) describe the same gene–drug relationships (EGFR–Gefitinib), which is associated in PharmGKB with a high level of evidence (Class=1). Figure 3
shows some of the data associated with this relationships in linked data. Values are extracted from the graph and are encoded in various manner. For example, values of
phenotypes are UMLS CUI, values of drug attributes are ATC codes
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propose using, handles directly RDF graphs as an input,
consequently limiting formatting efforts. GK generates
the attributes of the instances either as a list of feature
vectors or as a kernel matrix. Consequently, we provide
to Mustard the PGx linked data that we selected. Mustard
is designed to compute RDF node classification, whereas
we want computing link prediction. To adapt to Mustard,
we enriched the PGx data with artificial entities so we can
adapt link prediction to a classification task. Concretely,
we add entities to represent gene–drug relationships, each
related to a unique gene and drug. In addition, two classes
named associated and not associated are added to the
graph and related with pairs of the training set. For exam-
ple, a positive pair from the training set will be a node in
RDF, related to the class named associated. Mustard task
is to classify test pairs as associated or not. Finally, we
needed to invert the direction of some links in our graph
since Mustard allows exploring predicates in only one
direction, whereas we want kernel functions exploring the
full graph without considering the direction of predicates.
Enriching the graph with inverse predicates has been con-
sidered but this generates many cycles that are indeed
considered by some of the graph substructures then com-
puted by the kernel functions (see the next subsection for
details).
Graph kernels inMustard
In [34], de Vries et de Rooij proposed a general frame-
work, implemented within the Mustard library, with a
list of kernels to generate the features of RDF instances.
The framework works as follows: First, the neighbor-
hood of each instance, up to a certain depth, is extracted.
Additional file 2 proposes an example of SPARQL query
that returns the neighborhood, up to a lenght of 4, of
an example drug. Then, predefined substructures are
counted within the boundaries of this neighborhood.
The attributes of each instance are then the count, for
that instance, of the substructures extracted from all
neighborhoods.
Mustard includes 3 different types of substructures
defined below (see [34] for more details):
– Bag of labels: A bag of labels is simply the set of
vertex labels in the instance neighborhood.
– Walks, up to a certain length: A walk is a set of
consecutive edges in the graph.
– Sub-trees, up to a certain length: A sub-tree
originating at a vertex is the acyclic graph around
that vertex.
Note that the description of the substructures does
not require the distinction made in RDF graphs between
labels of nodes and labels of edges. Indeed the sub-
structure counting algorithms take care of reifying the
edges and transforming them to labeled nodes. By vary-
ing the size of the neighborhood and precising the type
of substructures, one obtain various feature vectors. We
list below parameters that can be changed to compute
kernels:
– Exploration depth : This parameter defines the depth
of instance neighborhood from which we extract and
count the substructures.
– Cycles traversal : During exploration, cycles can be
traversed either once, or multiple times. In the latter
case, the same nodes in the cycle get repeated, and
the obtained neighborhood is a Tree (an acyclic
graph) rooted at the instance vertex. Otherwise the
neighborhood is considered as a Sub-graph.
– Root constraint : If the neighborhood is a tree, we also
consider the constraint in which only substructures
that start from the root vertex are counted. This can
lead to a faster computation.
– Substructure depth : When counting substructures,
we can define the maximum length (respectively
depth) of the walks (resp. sub-trees).
– Minimum frequency: Two of the main differences
between RDF graphs and theoretical graphs usually
considered in graph mining are that vertices and
nodes in RDF have labels, and there is a large number
of different labels in the graph. Many labels may be
used only once. This leads, if considering labels, to
very specific graph patterns, which do not generalize
well. To alleviate this problem, Mustard enables
imposing a minimum frequency, under which a label
is not counted.
The obtained feature vectors are very sparse, which are
efficiently computed using matrix dot products, called
kernels. Those kernels are adapted to be computed by
Support Vector Machine (SVM) algorithm that are classi-
cally the learning algorithm on the basis of graph kernels.
We used this algorithm in this work.
Results and interpretation
Random Forest results
We trained and evaluated our model using the Weka
implementation of the RF and a 10-fold cross-validation.
First, we performed an information gain analysis, classi-
cally used for feature selection, and found out that the
feature named disease attribute was providing little infor-
mation to the classifier (InfoGain = 0.008). We decided to
remove this feature from both the training and test sets.
Table 3 presents the results of the evaluation on the model
trained with unbalanced data, and Table 2 the evaluation
on the model trained with balanced data.
We evaluate two concurrent models trained either with
a balanced set of positive and negative pairs (resp. 91
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Table 2 Results of the 10-fold cross-validation of our first RF
model
Class Precision Recall F-Measure
1 (positive) 0.944 0.904 0.924
0 (negative) 0.997 0.998 0.998
Weighted Average 0.996 0.996 0.996
This model is trained with 91 positive and 91 negative gene–drug relationships
and 91) or an unbalanced set (resp 91 and 182). The
model with balanced classes clearly overfits, with a F-
measure=0.996 (see Table 2). This is most probably due
to the fact that when formatting the data, negative pairs
generate much less instances, leading to a large unbalance
between positive (108,038) and negative (3197) instances
in the feature matrix. A larger set of negative pairs, leading
to a more balanced feature matrix, may temper the over-
fitting. In this case we obtained a F-measure of 0.729 (see
Table 3) and a root mean squared error of 0.385.
With this last model, we classified the 1760 pairs (rep-
resented by 984,460 instances) of our test set. The top-20
pairs predicated as positive according to our RF model are
provided online at [53, 54].
Graph kernel results
We used the Mustard library as an implementation of a
GK framework to perform the two next experiments.
Evaluating the impact of GK parameters The purpose
of the first experiment is to evaluate the impact of vari-
ous kernel settings on the RDF graph we consider here.
For each kernel a C-SVC (C-Support Vector Classifica-
tion) support vector machine from the LibSVM library
is trained. Each kernel is evaluated with a 10-fold cross-
validation, which is repeated 10 times itself with different
randomization seeds. Within each fold, SVM parameters
are optimized, again using a 10-fold cross-validation.
Table 4 illustrates how the F-measure of our model
changes depending on the substructure and the type of
neighborhood considered. Table 5 compares F-measures
obtained with various neighborhood depth, for a fixed
substructure and type of neighborhood. Surprisingly, the
F-measure is not strongly impacted by this parameter.
Table 3 Results of the 10-fold cross-validation of our second RF
model
Class Precision Recall F-Measure
1 (positive) 0.804 0.998 0.891
0 (negative) 0.994 0.547 0.706
Weighted Average 0.728 0.735 0.729
This model is trained on 91 positive and 182 negative gene–drug relationships
Table 4 Comparison of F-measures obtained with various
combination of substructure and neighborhood settings.
F-measures are averaged over two other parameters: the depth of
the neighborhood (d = 4, 6, 8, 10, 12, 15) and the length of the
substructures (l = 4, 6, 8, 10, 12, 15)
Substructures \ Neighborhood Graph Tree
Bag of Labels 0.763 0.781
Walks 0.777 0.797
Sub-trees 0.782 0.803
We think that this is due to the fact that most impor-
tant features are in a distance of 4. Table 6 illustrates
how F-measures can be impacted by the root constraint.
Table 7 shows the impact on the F-measure of imposing
a minimum frequency to the type of vertices and edges
considered in the mining.
Classifying candidate pharmacogenes In the second
experiment, we trained our model and applied it to our
test set to classify candidate pharmacogenes. Regarding
the evaluation of the model, a 10-fold cross-validation is
done and repeated 10 times with different randomization
seeds. Within each fold, we optimize the different kernel
settings again using 10-fold cross-validation. The reason
for optimizing the kernel settings within an inner cross-
validation instead of the selecting the best settings from
the previous experiment, is to avoid a model selection bias
which can lead to a misleading optimistic performance
evaluation as shown in [53, 54].
Table 8 presents the results of the evaluation of the
model trained with both balanced and unbalanced data.
We report the F-measure for the positive class, the aver-
age F-measure and the AUC-ROC. For the best average
F-measure, i.e., 0.807, the error rate for a 95% confidence
interval is 0.008.
With the unbalanced model, we classified the 1760
instances of our test set. The top-20 pairs predicated as
positive according to our GK model are provided online
at [55].
Result combination
We intersected the two lists of top candidate pairs
obtained by RF and GK, to keep only those present in
both classification. Then, we sorted the pairs by descend-
ing order of pRF . Table 9 presents the 20-top candidates
obtained by this method. We notice that with this ranking
Table 5 Comparison of F-measures obtained with different
depths of neighborhood
d=4 d=6 d=8 d=10 d=12 d=15
0.807 0.805 0.801 0.803 0.803 0.804
Neighborhood setting=Tree and substructures=Sub-trees
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Table 6 Comparison of F-measures obtained with and without
the root constraint
w/ Root constraint w/o Root constraint
Bag of Labels 0.479 0.781
Walks 0.753 0.797
Sub-trees 0.536 0.803
F-measures are averaged over the length of the substructures (l = 4, 6, 8, 10, 12, 15)
both pRF and pGK are closed to 1. A PGx expert (NCN)
examined the 20-top candidates within a manual litera-
ture study to evaluate their relevance and estimate their
interest for further investigation. Results of this examina-
tion are reported in the next subsection.
Interpretation
Among the top-20 candidates obtained with both pre-
dictions models (Table 9), unreleased gene–drug pairs
which should be further investigated were combined to
extensively-studied candidates, not surprinsingly mainly
in cancerology.
For instance, it is widely known that aberrant epidermal
growth factor receptor (EGFR) signaling lead to various
oncogenic phenotypes [56] and previous PGx invetiga-
tions have shown that the EGFR gene mutation status
was associated with EGFR-targeted agents efficacy such
as Erlotinib’s (rank 2) in the case of non-small cell lung
cancer (NSCLC) [56, 57]. In addition to its single agent
activity, it has also been shown that this tyrosine kinase
inhibitor acts in synergy with standard chemotherapy
such as Fluorouracil in various cancer patients [58, 59] and
we were able to pair Fluorouracil with the EGFR gene as
well (rank 3).
Conversely, theMAP3K1 gene’s association with Carbo-
platin (rank 1) seemed novel and yet, in a genome-wide
association study on advanced NSCLC patients treated
with this antineoplastic chemotherapy drug, a single
nucleotide polymorphism in the DSCAM gene has been
identified as a prognostic biomarker candidate [60]. This
supports our drug-gene pair in rank 6 and gives insights
on possible MAP3K1 × DSCAM synergy that should be
further investigated.
Those various outputs (confirming bibliography or
unreleased) show that our approach could be of value in 1)
strengthening PGx knowledge and facilitate its translation
in practice and 2) leading to novel investigations in order
to better identify the complex synergies in action.
Table 7 Comparison of F-measures obtained with different
minimum frequency settings
Min. frequency 2 4 8 16 32
F-measure 0.794 0.780 0.798 0.796 0.774
Neighborhood setting=Tree and substructures=Walks
Table 8 Results of the 10-fold cross-validation of our Graph
Kernel/SVM model
F-measure Avg. F-measure AUC-ROC
Balanced 0.770 0.761 0.840
Unbalanced 0.746 0.807 0.905
Models are trained with 91 positive and 91 negative examples for the Balanced
model and 91 and 182 for the Unbalanced
Discussion
We considered first the RF algorithm because it has been
successively applied for the prediction of drug–drug inter-
actions from a set of RDF statements [37, 48]. The avail-
ability of the Mustard library and its results in term of
node classification motivates us to compare RF with GK.
One drawback of the Graph Kernel method is that it is not
always possible to know which part of the graph data have
the biggest contribution to classification since a graphs is
classified by similarity. This may motivate the investiga-
tion of other subgraph mining methods that may be more
informative on the weights of substructures in the classifi-
cation. One may consider techniques such as gBoost [61]
that progressively collects informative patterns, or gSpan
[62] that enumerates frequent subgraph used as features
for classification.
Table 9 20-Top candidates of gene–drug pairs predicted from
our PGx linked data
Rank Gene Drug pRF pGK
1 MAP3K1 Carboplatin 0.993 0.991
2 EGFR Erlotinib 0.992 0.980
3 EGFR Fluorouracil 0.989 0.966
4 FCER1G Aspirin 0.988 0.993
5 MAP3K1 Erlotinib 0.988 0.830
6 DSCAM Carboplatin 0.979 0.974
7 CHIA Aspirin 0.979 0.911
8 GP6 Aspirin 0.979 0.976
9 ACE Sidenafil 0.979 0.911
10 TPMT Cyclophosphamide 0.975 0.994
11 CYP2B6 Nicotine 0.973 0.912
12 PTGER3 Aspirin 0.967 0.965
13 NTRK1 Aspirin 0.967 0.992
14 EXO1 Fluorouracil 0.966 0.694
15 ERBB2 Trastuzumab 0.964 0.998
16 CYP2B6 Olanzapine 0.964 0.965
17 HLA-DQ1 Azathioprine 0.963 0.931
18 HMGCR Simvastatin 0.963 0.996
19 CYBA Simvastatin 0.961 0.973
20 HLA-DRB1 Mercaptopurine 0.961 0.966
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RF algorithm performs correctly (F-m= 0.73) in the
frame of our case study, but presents several limitations.
First, RF is limited by our usage of a multi-instance rep-
resentation of data, i.e., data about one gene–drug pair
is represented in the feature matrix by several lines [52].
Because our dataset contains much more data about pos-
itive examples than data about negatives, it results that
if we balance the number of positive and negative exam-
ples in the training set (respectively 91 and 91), the actual
number of lines (i.e., instances) in the matrix describ-
ing positive examples is much larger than for negatives
(respectively 108,038 and 3,197). However, our experi-
ments showed that initial selection of negative examples,
as well as keeping a certain unbalance, is important. This
large unbalance lead the RF to an overfitting, i.e., an
instance to classify will most probably be similar to one
of the numerous descriptions of positive examples and
be classified as positive. We overcome this drawback by
doubling the number of negative examples in our training
set. This unbalancing of examples (respectively 91 pos-
itives and 182 negatives) resulted in a reduction of the
unbalance in the feature matrix (respectively 108,038 and
57,885). Here we can note that the second set of negative
example is described by much more instances than the
first one, what let us see that our random pick of negative
examples in the large set of gene-drug relationships not
referenced by DGIdb impacts to some extent the results of
our approach.
Another limitation of RF is that it requires a format-
ting of the graph data and then to select a set of features.
We achieved this selection manually to retain 6 fea-
tures, and then apply a standard feature selection method
(Information Gain) that enabled us to filter one use-
less feature (disease attribute such as the MeSH class of
the disease).
Our experiment shows that GK achieves globally better
than RF, and that the Mustard library offers many facili-
ties to mine RDF data. In addition, it provides us several
insights on the features that are more relevant to con-
sider when mining our PGx linked data. For example, it
seems that considering only the close neighborhood (d=4)
of instances to classify is sufficient in our case. Also, in
the case of a constrained graph, as the one we designed,
considering substructure in the neighborhood of instance
may not be of primary importance. This may be associ-
ated to the fact that we limited the size and connectivity of
the data graph, and consequently knowing solely the label
of a set of edges and of vertices may enable to reconstruct
a path or a subgraph in the neighborhood of an instance.
Our selection of data sources may be discussed, par-
ticularly because some of those are not open. Of course
adding new sources would be of interest. Indeed, our
choice for the linked data framework is motivated by the
fact that we want to ease the addition/removal of data
sources for enabling the selection of best features out
of many sources without considering if they are open
or not. In regards with the results from previous works
[40, 41], we think that sources of triples extracted from
the literature would be particularly valuable, such as those
extracted in [25]. Because GK considers data directly in
the form of a graph, one could want to mine directly LOD
resources, without particular selection. However, the large
number of available data in the LOD, includingmany non-
informative metadata, makes this still challenging. We
decided to use multiple data sources, with various license
agreement. Further work could evaluate the impact of
adding/removing data sources, then offering the oppor-
tunity to compare the importance of open data vs. not
open data.
A limitation to our approach is related to the field of
PGx itself since only few (91) gene–drug relationships
have a high level of evidence according to PharmGKB,
making our training set relatively small. One way of
enlarging the size of the training set would be to consider
gene variant–drug relationships, instead of gene–drug,
that have two advantages: being more numerous, but also
renderingmore precisely the state of the art of PGx knowl-
edge. Indeed, a gene may host two (or more) variants, one
that impacts drug response and one that does not.
Two biases are to consider when interpreting the results.
First, negative examples are gene–drug relationships not
listed in DGIdb, which includes known and predicted
candidates frommany databases. Consequently, negatives
are likely not to be related, instead of not being related,
but to our knowledge no existing resource lists nega-
tive gene–drug relationships. Second, tested examples are
likely to be related since they are listed in PharmGKB
with a low level of confidence. However, our goal is pri-
oritize these candidates, instead of detecting negatives
from those.
Conclusion
This article is a proposal to help validating candidate phar-
macogenes by learning from PGx linked data. More pre-
cisely, we selected and interconnected data relevant to the
PGx domain in the form of a large RDF graph. Then, we
formatted these data to train and compare a RF and a GK
classifier. These two classifiers were evaluated and used to
identify and rank candidate pharmacogenes. GK achieves
a F-measure of 0.81, whereas RF reaches 0.73. Top can-
didate pharmacogenes pointed out by our approach are
provided and interpretated in this article. Top candidates
that are not already extensively studied will be further
investigated by PGx experts. Results we obtained with
the GK library named Mustard are particularly promising
both for our application domain, i.e., validating pharma-
cogenes, and more broadly for the mining of biomedical
linked data.
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Additional files
Additional file 1: SPARQL query example 1. This text file contains the
SPARQL query we apply on our PGx linked data to obtain the data graph
represented in Fig. 3. This query includes the definition of prefixes
mentioned in Figs. 2 and 3. This query takes about 30 s on our https://
pgxlod.loria.fr server. (TXT 2 kb)
Additional file 2: SPARQL query example 2. This text file contains an
example of SPARQL query that enable to explore the vicinity of an entity.
This particular query returns the RDF graph surrounding, within a lenght of
4, the node pharmgkb:PA451906 that represents the warfarin, an
anticoagulant drug. (TXT 392 bytes)
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